Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Anti PD-1 protitelesa : uporaba, delovanje, neželeni učinki
Authors:ID Ocvirk, Janja (Author)
Files:.pdf PDF - Presentation file, download (214,70 KB)
MD5: B3823B0B5E4DB54721A500EAB10D2292
PID: 20.500.12556/dirros/30c34c6e-d6a2-412a-9995-880cc3f11228
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Protein programirane celične smrti 1:PD-1 (Programmed cell death protein 1) je transmembranski protein, ki je izražen na celicah T, B, NK ter monocitih in dendritičnih celicah. Vezava med PD-1 in njegovimi ligandi zavira tumorsko celično apoptozo, spodbuja izčrpanost T-celic in preprečuje aktiven antitu¬morski odziv, kar posledično omogoča nemoteno rast in razvoj tumorskih celic. Zaviralca receptorja PD-1, pembrolizumab in nivolumab, že uporabljamo v zdravljenju različnih vrst napredovalega raka, kot so: melanom, nedrobnocelični karcinom pljuč, Hodgkinov limfom in karcinom ledvic. Na zdravljenje odgovori zelo različno število bolnikov, kar je odvisno od indikacije in linije zdravljenja, to je od pri 18 do 80 odstotkih bolnikov. Posebnosti zdravljenja z imuno¬terapijo so zelo dolgotrajne remisije, pri posameznih bolnikih pa bomo morebiti upali govoriti celo o ozdravitvi. Najpogostejši neželeni učinki so utrujenost, srbečica, izpuščaji, driska in slabost. Najresnejši neželeni učinki so imunsko pogojeni neželeni učinki in hude z infuzijo povezane reakcije. Imunsko pogojeni neželeni učinki so kolitis, tiroiditis, pneumonitis, hepatitis in nefritis.
Keywords:imunoterapija, anti-PD-1 protitelesa, zaviralci receptorjev
Publication status:Published
Publication version:Version of Record
Year of publishing:2017
Number of pages:str. 22-25
Numbering:Letn. 21, št. 2
PID:20.500.12556/DiRROS-8195 New window
UDC:616-006
ISSN on article:1408-1741
COBISS.SI-ID:2841467 New window
Copyright:by Authors
Publication date in DiRROS:16.03.2018
Views:3543
Downloads:713
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija. strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:16.03.2018

Secondary language

Language:English
Title:Anti-PD-1 antibodies : use, action, side effects
Abstract:Programmed cell death protein 1 (PD-1) is a transmembrane protein expressed in T, B, NK cells, monocytes, and dendritic cells. The binding of PD-1 to its ligands inhibits tumor cell apoptosis, stimulates T-cell depletion, and prevents active antitumor response, which consequently enables an uninhibited growth and development of tumor cells. PD-1 receptor inhibitors pembrolizumab and nivolumab are already used in the treatment of various types of advanced cancer, such as melanoma, non-small cell lung cancer, Hodgkin’s lymphoma, and renal carcinoma. Depending on the indication and line of treatment, a different number of patients responds to the treatment success¬fully, ranging from 18 % to 80 % of patients. The particularities of treatment with immunotherapy include very long-lasting remissions and, in individual patients, we might even dare talk about cure. The most common side effects are fatigue, pruritus, rash, diarrhea, and nausea. Among the most serious side effects are immune-rela¬ted adverse reactions – including colitis, thyroiditis, pneumonitis, hepatitis, and nephritis – and severe infusion-related reactions.


Archive

niGradiv

Back